Have a personal or library account? Click to login
Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies Cover

Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies

Acta Pharmaceutica
Volume 71 (2021): Issue 2 (June 2021)
By: Safa Daoud,  Shada J. Alabed and  Lina A. Dahabiyeh  
Open Access
|Nov 2020

Authors

Safa Daoud

s_daoud@asu.edu.jo

Department of Pharmaceutical, Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science, Private University, Amman, Jordan

Shada J. Alabed

Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan

Lina A. Dahabiyeh

Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan
DOI: https://doi.org/10.2478/acph-2021-0016 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 163 - 174
Accepted on: Jun 2, 2020
|
Published on: Nov 4, 2020
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
COVID-19,
main protease,
pharmacophore,
structure-based modeling,
docking study,
remdesivir,
repurposing
Related subjects:
Pharmacy,
Pharmacy, other

© 2020 Safa Daoud, Shada J. Alabed, Lina A. Dahabiyeh, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 71 (2021): Issue 2 (June 2021)Next article